is naltrexone a glp-1 vs For Alcohol Use Disorder Obesity drugs under review: Semaglutide,
Description
This is not dangerous
Telehealth GLP-1 programs work best for patients comfortable with self-injection, capable of articulating side effects remotely, and without complex metabolic comorbidities requiring hands-on assessment
In 2023, an estimated 13.3 million Medicare beneficiaries enrolled in Parts A and B had obesity or overweight, based on having BMI of 27 or more recorded in claims or encounter data, or 24% of Medicare beneficiaries overall (Figure 1)
Bioavailability: Even with SNAC technology, oral semaglutide has only 0.4-1% bioavailability compared to injectable semaglutide
